Advertisement

Advertisement

PHAT Stock Latest News

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

The FlyPhathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

Phathom Pharmaceuticals management to meet with Cantor

PremiumThe Fly

Phathom Pharmaceuticals management to meet with Cantor

18d ago

Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up

PremiumCompany Announcements

Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up

1M ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

PremiumThe Fly

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

1M ago

Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating

PremiumRatings

Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating

1M ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

PremiumThe FlyPhathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

1M ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

The Fly

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

1M ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

The Fly

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

1M ago

Phathom Pharmaceuticals Announces $130 Million Public Offering

PremiumCompany Announcements

Phathom Pharmaceuticals Announces $130 Million Public Offering

3M ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

PremiumThe Fly

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

3M ago

Closing Bell Movers: Defense stocks surge on Trump military budget comments

PremiumThe Fly

Closing Bell Movers: Defense stocks surge on Trump military budget comments

3M ago

Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M

PremiumThe Fly

Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M

3M ago

Phathom Pharmaceuticals announces common stock offering, no amount given

PremiumThe FlyPhathom Pharmaceuticals announces common stock offering, no amount given

3M ago

Phathom Pharmaceuticals files automatic mixed securities shelf

The Fly

Phathom Pharmaceuticals files automatic mixed securities shelf

3M ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

The Fly

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

3M ago

Needham ups Vaxcyte target, adds to Conviction List

PremiumThe Fly

Needham ups Vaxcyte target, adds to Conviction List

3M ago

Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks

PremiumStock Analysis & Ideas

Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks

4M ago

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

PremiumThe Fly

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

4M ago

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

PremiumThe Fly

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

4M ago

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

PremiumThe FlyPhathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

5M ago

Phathom Pharmaceuticals Begins Phase 2 EoE Trial

Company Announcements

Phathom Pharmaceuticals Begins Phase 2 EoE Trial

5M ago

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges

Company Announcements

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >